Welcome to Anaesthesia-az

an international information resource for healthcare professionals about our anaesthesia products Naropin (ropivacaine), Diprivan (propofol) and EMLA, provided by AstraZeneca. This site is not intended for the following audiences who should use the following links: US Citizens should visit AstraZeneca-US.com, UK Citizens should visit AstraZeneca.co.uk, Patients (non US & UK) should visit PatientHealthInternational.com, Journalists should visit AstraZenecaPressOffice.com.

  • Highlights

    Diprivan (propofol) - general anaesthesia, intravenous anaesthetic, ICU sedation.
    Diprivan (propofol) is a short-acting intravenous anaesthetic agent suitable for both induction and maintenance of general anaesthesia, ICU sedation and sedation during diagnostic or surgical procedures. 

    Naropin (ropivacaine HCI) local anaesthetic
    Naropin® (ropivacaine) is the most recent long-acting local anaesthetic introduced by Astra (AstraZeneca). Naropin is closely related to mepivacaine and bupivacaine, and was in fact synthesised simultaneously with those two local anaesthetics by af Ekenstam as early as in the mid 1950's.

    EMLA is the first topical anaesthetic able to numb intact skin prior to needle insertion procedures and superficial surgical procedures. EMLA is the only topical anaesthetic with proven efficacy of all three indications - intact skin, genital mucous membranes and leg ulcers.

Drug related information may refer to unlicensed products or uses, which may not be approved in your own country. Please consult your local prescribing information. No information provided on this site should be taken as a recommendation as to the use of any product.